Activation of 5-lipoxygenase is Required for Nicotine Mediated Epithelial-mesenchymal Transition and Tumor Cell Growth
Overview
Authors
Affiliations
Nicotine is shown to be one of the carcinogenic agents for gastric cancer. Perturbation of epithelial-mesenchymal transition (EMT) results in loss of intracellular adhesions leading to tumor progression. In this study, we examined the underlying mechanism of the long-term effects of nicotine on tumor progression in human gastric cancer cells. Nicotine activated 5-lipoxygenase (5-LOX) in three gastric cancer cell lines (MKN-45, MKN-28 and AGS). Cells treated with nicotine dose- and time-dependently induced cell proliferation, invasion and suppressed apoptosis. In addition, cell cycle progression analysis revealed that activation of 5-LOX modulated the G1/S phase transition regulatory proteins and caused cell proliferation. MK886 (5-LOX activating protein inhibitor) mediated the induction of apoptosis by elevation of caspase-3 and Bax/Bcl2 ratio. Abrogation of 5-LOX repressed featured molecular markers of EMT (inactivation of E-cadherin and activation of transcriptional repressor Snail). Blockade of 5-LOX signaling resulted in downregulation of cyclin D1, matrix metalloproteinase (MMP-7, -9), urokinase plasminogen activator (uPA) and its receptor (uPAR), and pro-apoptotic proteins. Furthermore, suppression of Snail and induction of E-cadherin is extracellular signal-regulated kinase (Erk)-dependent. Thus, we conclude that the promotion effect of nicotine on cancer cell progression and EMT is mediated by Erk/5-LOX signaling pathway.
Singh A, Batra A, Upadhaya A, Gupta S, K P H, Dey S Front Oncol. 2022; 12:851807.
PMID: 35875090 PMC: 9300851. DOI: 10.3389/fonc.2022.851807.
Tang J, Zhang C, Lin J, Duan P, Long J, Zhu H Cancer Med. 2021; 10(15):5246-5255.
PMID: 34121352 PMC: 8335819. DOI: 10.1002/cam4.4066.
Role of the parasympathetic nervous system in cancer initiation and progression.
Tibensky M, Mravec B Clin Transl Oncol. 2020; 23(4):669-681.
PMID: 32770391 DOI: 10.1007/s12094-020-02465-w.
Xie J, Huang X, Chen Q, Ma Y, Zhao Y, Liu L Mol Cancer. 2020; 19(1):114.
PMID: 32650804 PMC: 7350710. DOI: 10.1186/s12943-020-01223-4.
Wang Y, Geng H, Zhao L, Zhang Z, Xie D, Zhang T Int J Clin Exp Pathol. 2020; 10(8):8243-8252.
PMID: 31966675 PMC: 6965368.